Immunexpress' technology, SeptID™, can identify sepsis-causing bacteria as Gram-positive, Gram-negative or mixed. SeptID™ can accurately determine Gram stain status from a whole blood sample containing a microbe from a sepsis patient in approximately one hour.

Rolland D. Carlson, Ph.D., Chief Executive Officer of Immunexpress, said, "Our technology lends itself to rapid test development. It is currently formatted for an RT-qPCR machine but is not restricted to a particular technology. Our SeptID™ technology could transform the way clinicians recommend antibiotics for sepsis patients, and we are seeking strategic partners to help us achieve this goal."